# CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma

> **NCT03425279** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioAtla, Inc.** · enrollment: 245 (actual)

## Conditions studied

- Undifferentiated Pleomorphic Sarcoma
- Myxofibrosarcoma

## Interventions

- **BIOLOGICAL:** CAB-AXL-ADC
- **BIOLOGICAL:** PD-1 inhibitor

## Key facts

- **NCT ID:** NCT03425279
- **Lead sponsor:** BioAtla, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-15
- **Primary completion:** 2025-01-08
- **Final completion:** 2025-01-08
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03425279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03425279, "CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03425279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*